| Serial Number | 97796895 |
| Word Mark | A2 BIOTHERAPEUTICS |
| Filing Date | Wednesday, February 15, 2023 |
| Status | 732 - THIRD EXTENSION - GRANTED |
| Status Date | Thursday, November 13, 2025 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, March 26, 2024 |
| Goods and Services | Therapeutics in the nature of cells, proteins and protein complexes for the treatment and prevention of cancer, inflammation, and inflammatory diseases; biotherapeutics for the treatment and prevention of cancer, inflammation, and inflammatory diseases; medicines for the treatment and prevention of cancer, inflammation, and inflammatory diseases; pharmaceutical products for the treatment and prevention of cancer, inflammation, and inflammatory diseases; therapeutic targets, namely, proteins or protein complexes, for the treatment and prevention of cancer, inflammation and inflammatory diseases; therapeutic cells, therapeutic proteins and therapeutic antibodies for human use for the treatment and prevention of cancer, inflammation and inflammatory diseases; therapeutics and cell therapies in the nature of cells, proteins and protein complexes for the treatment of cancer, inflammation, and inflammatory diseases; engineered cell therapies in the nature of cells, proteins and protein complexes for medical purposes, namely, the treatment and prevention of cancer, inflammation and inflammatory diseases; engineered cell therapy platforms consisting of modified cells, cell receptors, proteins and protein complexes; cell platforms consisting of modified cells, cell receptors, proteins and protein complexes for the treatment and prevention of cancer, inflammation and inflammatory diseases; technology platforms for developing and engineering therapeutic cells, therapeutic proteins, therapeutic antibodies, therapeutics and cellular therapies for the treatment and prevention of cancer, inflammation, and inflammatory diseases; platform for autologous and allogeneic cell manufacturing; therapeutics and cell therapies targeting targets lost in tumors for the treatment and prevention of cancer, inflammation and inflammatory diseases; gene therapy products, namely, genetically engineered tissues for transplant purposes |
| NOT AVAILABLE | BIOTHERAPEUTICS |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, March 6, 2023 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | A2 Biotherapeutics, Inc. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | Agoura Hills, CA 91301 |
| Party Name | A2 Biotherapeutics, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Agoura Hills, CA 91301 |
| Event Date | Event Description |
| Saturday, February 18, 2023 | NEW APPLICATION ENTERED |
| Monday, March 6, 2023 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Tuesday, November 14, 2023 | ASSIGNED TO EXAMINER |
| Friday, November 17, 2023 | PRIORITY ACTION WRITTEN |
| Friday, November 17, 2023 | PRIORITY ACTION E-MAILED |
| Friday, November 17, 2023 | NOTIFICATION OF PRIORITY ACTION E-MAILED |
| Friday, February 16, 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Friday, February 16, 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Friday, February 16, 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Friday, February 16, 2024 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, March 6, 2024 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Wednesday, March 6, 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, March 26, 2024 | PUBLISHED FOR OPPOSITION |
| Tuesday, March 26, 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, May 21, 2024 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Tuesday, November 12, 2024 | SOU TEAS EXTENSION RECEIVED |
| Tuesday, November 12, 2024 | SOU EXTENSION 1 FILED |
| Wednesday, December 11, 2024 | SOU EXTENSION 1 GRANTED |
| Wednesday, December 11, 2024 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Monday, May 12, 2025 | SOU TEAS EXTENSION RECEIVED |
| Monday, May 12, 2025 | SOU EXTENSION 2 FILED |
| Monday, May 12, 2025 | SOU EXTENSION 2 GRANTED |
| Tuesday, May 13, 2025 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Thursday, November 13, 2025 | SOU TEAS EXTENSION RECEIVED |
| Thursday, November 13, 2025 | SOU EXTENSION 3 FILED |
| Thursday, November 13, 2025 | SOU EXTENSION 3 GRANTED |
| Friday, November 14, 2025 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |